Constitutively active nuclear factor-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M2" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><path id="x1D705" d="M484 406q0 -21 -22 -38q-10 -7 -18 -1q-15 11 -30 11q-30 0 -77.5 -37t-74.5 -67l79 -168q11 -23 19.5 -34.5t13 -14t10.5 -2.5q9 0 30 17.5t40 42.5l17 -23q-31 -45 -57.5 -69.5t-40.5 -29.5t-31 -5q-18 0 -32 13.5t-35 55.5q-34 71 -69 160q-36 -32 -59 -56&#xA;q-12 -27 -36 -158q-44 -7 -77 -15l-5 7l82 349q6 25 -2 25q-16 0 -72 -41l-14 22q44 41 89 69.5t66 28.5q19 0 19 -32q0 -16 -6 -43l-35 -160l146 143q94 92 136 92q20 0 33 -12t13 -30z" /></g>

		
	
</svg>B (NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M3" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B) is integral to the survival of Hodgkin/Reed-Sternberg cells (H/RS) in Hodgkin lymphoma (HL). To investigate NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M4" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B pathway proteins in pediatric HL, we utilized a tissue microarray compiled from 102 children enrolled in the Children's Oncology Group intermediate-risk clinical trial AHOD0031 (56 male, 78 Caucasian, median age 15 years (range 1&#x2013;20 years), 85 nodular sclerosing subtype, 23 Epstein-Barr virus (EBV) positive, and 24 refractory/relapsed disease).  We examined the intensity, localization, and pathway correlations of NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M5" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B pathway proteins (Rel-A/p65, Rel-B, c-Rel, NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M6" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B1, NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M7" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B2, I<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M8" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B-<svg     style="vertical-align:-0.1638pt;width:9.7749996px;" id="M9" height="7.9499998" version="1.1" viewBox="0 0 9.7749996 7.9499998" width="9.7749996"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><path id="x1D6FC" d="M545 106q-67 -118 -134 -118q-24 0 -40 37.5t-30 129.5h-2q-47 -72 -103 -119.5t-108 -47.5q-47 0 -76 45.5t-29 119.5q0 113 85 204t174 91q47 0 70 -33.5t43 -119.5h3q32 47 80 140l55 13l10 -9q-47 -80 -138 -201q17 -99 27.5 -136t22.5 -37q23 0 69 61zM333 204&#xA;q-14 98 -31 149.5t-50 51.5q-49 0 -94 -70t-45 -164q0 -55 15.5 -86t40.5 -31q70 0 164 150z" /></g>

		
	
</svg>, IKK-<svg     style="vertical-align:-0.1638pt;width:9.7749996px;" id="M10" height="7.9499998" version="1.1" viewBox="0 0 9.7749996 7.9499998" width="9.7749996"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D6FC"/></g>

		
	
</svg>, IKK-<svg     style="vertical-align:-3.56265pt;width:10px;" id="M11" height="16.6625" version="1.1" viewBox="0 0 10 16.6625" width="10"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,12.162)"><path id="x1D6FD" d="M558 587q0 -32 -14 -61t-40 -53.5t-48.5 -41t-54.5 -36.5q144 -51 144 -174q0 -55 -43.5 -108t-104.5 -87q-77 -42 -131 -42q-31 0 -54 20t-31 47l11 18q48 -29 108 -29q79 0 119.5 43t40.5 109t-44.5 107.5t-119.5 50.5l22 47q34 1 65 21q96 61 96 157q0 42 -24 67.5&#xA;t-62 25.5q-24 0 -43.5 -9t-35 -29.5t-27 -44t-22.5 -63t-19.5 -75.5t-18.5 -91q-57 -294 -68 -380q-26 -190 -35 -200q-26 -31 -97 -37l-4 26q19 9 48 170l77 413q23 121 52.5 187.5t83.5 114.5q70 62 148 62q51 0 88.5 -34t37.5 -91z" /></g>

		
	
</svg>, IKK-<svg     style="vertical-align:-3.56265pt;width:8.6374998px;" id="M12" height="12.175" version="1.1" viewBox="0 0 8.6374998 12.175" width="8.6374998"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><path id="x1D6FE" d="M478 372q0 -39 -31 -97t-61 -98t-78 -98q-45 -55 -73 -102q-13 -79 -13 -197q-11 -11 -43.5 -25.5t-53.5 -15.5l-15 17q5 35 26 101.5t47 123.5q8 72 -1.5 174.5t-37.5 178.5q-14 37 -29 37q-20 0 -67 -65l-25 21q37 60 73 90.5t63 30.5q47 0 72 -112q13 -56 17.5 -141.5&#xA;t0.5 -143.5h2q155 193 155 297q0 26 -12 47q-5 8 -5 15q0 16 12.5 27t29.5 11q21 0 34 -21t13 -55z" /></g>

		
	
</svg>/NEMO, NIK, and A20), as well as their associations with EBV status and clinical outcome. NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M13" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B pathway proteins were overexpressed in pediatric HL patients compared to controls. Patients with EBV&#x2212; tumors, or with rapid early therapy response, had tightly coordinated regulation of NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M14" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B pathway proteins, whereas patients with EBV+ tumors, or slow early therapy response, had little coordinated NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M15" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B pathway regulation. High NIK expression was associated with a slow response to therapy and decreased EFS.  Elevated Rel-B, NIK, and the NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M16" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B inhibitor A20 were associated with decreased EFS in multivariate analysis. These studies suggest a pivotal role for the NF-<svg     style="vertical-align:-0.1638pt;width:8.7375002px;" id="M17" height="7.9499998" version="1.1" viewBox="0 0 8.7375002 7.9499998" width="8.7375002"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,-0,0,-.017,.062,7.675)"><use xlink:href="#x1D705"/></g>

		
	
</svg>B pathway in therapy response and patient survival in Hodgkin
lymphoma.

Terzah M. Horton

Andrea M. Sheehan

Dolores L&#xf3;pez-Terrada

Robert  E. Hutchison

Sonia Narendra

Meng-Fen Wu

Hao Liu

Analysis of NF-<svg style="vertical-align:-0.0pt" height="7.9749999" version="1.1" viewBox="0 0 9.6499996 7.9749999" width="9.6499996" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.017,-0,0,-.017,.062,7.913)"><path id="x1D73F" d="M276 462l-36 -168l129 101q83 67 140 67q68 0 68 -50q0 -62 -59 -62q-18 0 -28.5 7t-13.5 16t-10.5 16t-19.5 7q-14 0 -49 -29l-114 -93l112 -199q18 -31 39 -41.5t64 -10.5l-5 -23h-269l5 23h29q28 0 28 15q0 14 -13 36l-60 107l-42 -181h-116l82 363q4 15 4 28&#xA;q0 17 -26 17q-15 0 -32 -3l-3 23z" /></g></svg>B Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome&#x2014;A Children's Oncology Group Study

Small B cell lymphoma is a morphological designation to a group of B cell lymphomas which are composed of a clonal population of small lymphoid cells. The subtypes of this category have diagnostically distinct characteristics and different clinical behaviors and treatment. Correct diagnosis and classification of these subsets depend on the integration of morphologic, immunophenotypic, and molecular genetic features. In this paper, differential diagnosis of this category of tumors and a practical approach based on biomarker evaluation are discussed.

Kathryn Rizzo

Mehdi Nassiri

Diagnostic Workup of Small B Cell Lymphomas: A Laboratory Perspective

During the last 30 years, combined chemotherapy regimens with radiotherapy or not significantly improved the prognosis for patients with Hodgkin lymphoma. We retrospectively studied 58 children (35 boys and 23 girls) with Hodgkin lymphoma who were treated at our institution during the period 1987&#x2013;2006 and we correlated age, sex, stage, histology, and therapy with the outcome of patients. Of our patients, 9 children were 8 years old or younger. Nodular sclerosis was the predominant histology subtype (69&#x25;), whereas 26 patients (45&#x25;) had advanced disease (stage III or IV). Chemotherapy (CT) with various drug combinations, according to the period of treatment plus low-dose involved field radiation therapy (IFRT), was used in all patients. Five children experienced relapse and in 3 other patients second or third malignancies were documented. The overall survival was found to be 98&#x25;. No factors related to the outcome could be detected. The prognosis of children with Hodgkin lymphoma is excellent with CT combined with low dose IFRT but in long-time survivors late effects of the combined modality treatment are still issues of major concern. Longer followup of a greater number of patients is necessary to detect prognostic factors related to the outcome of children with Hodgkin lymphoma and to identify some patients who would be treated without radiation.

Apostolos Pourtsidis

Dimitrios Doganis

Margarita Baka

Despina Bouhoutsou


							Maria Varvoutsi

Maria Synodinou

Katerina Strantzia

Helen Kosmidis

Successful Treatment in Children with Hodgkin Lymphoma in Greece; A 20-Year Experience in a Single Institution

Current treatment for cutaneous T-cell lymphoma includes phototherapy, which involves either the use of narrowband ultraviolet B light or <svg style="vertical-align:-3.27605pt;width:33.424999px;" id="M1" height="15.25" version="1.1" viewBox="0 0 33.424999 15.25" width="33.424999"      xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,0,0,-.017,.062,11.113)"><path id="x55" d="M716 650v-28q-46 -3 -65 -15.5t-22 -43.5q-6 -54 -6 -162v-82q0 -184 -75 -264q-68 -69 -180 -69q-98 0 -160 48q-88 67 -88 238v249q0 66 -13.5 81t-73.5 20v28h258v-28q-59 -4 -72.5 -19t-13.5 -82v-227q0 -122 48 -188t140 -66q189 0 189 286v75q0 111 -7 165&#xD;&#xA;q-4 29 -24 40.5t-73 15.5v28h238z"/></g><g transform="matrix(.017,0,0,-.017,12.574,11.113)"><path id="x56" d="M687 650v-28q-52 -6 -71.5 -23t-47.5 -83q-142 -346 -208 -527h-31q-119 325 -207 545q-21 54 -39.5 68.5t-65.5 19.5v28h245v-28q-52 -5 -61.5 -15.5t3.5 -43.5q55 -157 166 -437h2q120 303 158 421q14 43 3.5 55.5t-71.5 19.5v28h225z"/></g>

			<g transform="matrix(.012,0,0,-.012,24.525,15.188)"><path id="x41" d="M673 0h-245v28q47 6 58 16t1 39l-55 154h-213q-31 -87 -36 -129q-16 -47 -5 -61t68 -19v-28h-226v28q50 7 68.5 23.5t43.5 80.5l214 524l24 9l193 -536q23 -63 41.5 -79.5t68.5 -21.5v-28zM418 280l-81 255h-2q-74 -197 -101 -255h184z"/></g>

		
	
</svg> in combination with a psoralen photosensitiser. Therapy typically involves administration of the photosensitiser followed by topical exposure to <svg style="vertical-align:-3.27605pt;width:33.424999px;" id="M2" height="15.25" version="1.1" viewBox="0 0 33.424999 15.25" width="33.424999"      xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,0,0,-.017,.062,11.113)"><use xlink:href="#x55"/></g><g transform="matrix(.017,0,0,-.017,12.574,11.113)"><use xlink:href="#x56"/></g>

			<g transform="matrix(.012,0,0,-.012,24.525,15.188)"><use xlink:href="#x41"/></g>

		
	
</svg>. A different approach is extracorporeal photopheresis, an <i  >ex vivo</i> strategy which is used for more advanced stages of disease. Further, histone deacetylase inhibitors are emerging as potent anticancer agents with suberoylanilide hydroxamic acid and depsipeptide, having received FDA approval for the treatment of cutaneous T-cell lymphoma. We have developed <svg style="vertical-align:-3.27605pt;width:33.424999px;" id="M3" height="15.25" version="1.1" viewBox="0 0 33.424999 15.25" width="33.424999"      xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,0,0,-.017,.062,11.113)"><use xlink:href="#x55"/></g><g transform="matrix(.017,0,0,-.017,12.574,11.113)"><use xlink:href="#x56"/></g>

			<g transform="matrix(.012,0,0,-.012,24.525,15.188)"><use xlink:href="#x41"/></g>

		
	
</svg>Sens, an extremely potent, DNA minor groove-binding <svg style="vertical-align:-3.27605pt;width:33.424999px;" id="M4" height="15.25" version="1.1" viewBox="0 0 33.424999 15.25" width="33.424999"      xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,0,0,-.017,.062,11.113)"><use xlink:href="#x55"/></g><g transform="matrix(.017,0,0,-.017,12.574,11.113)"><use xlink:href="#x56"/></g>

			<g transform="matrix(.012,0,0,-.012,24.525,15.188)"><use xlink:href="#x41"/></g>

		
	
</svg> sensitizer for potential use in phototherapy. We have previously demonstrated the extreme photopotency of <svg style="vertical-align:-3.27605pt;width:33.424999px;" id="M5" height="15.25" version="1.1" viewBox="0 0 33.424999 15.25" width="33.424999"      xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,0,0,-.017,.062,11.113)"><use xlink:href="#x55"/></g><g transform="matrix(.017,0,0,-.017,12.574,11.113)"><use xlink:href="#x56"/></g>

			<g transform="matrix(.012,0,0,-.012,24.525,15.188)"><use xlink:href="#x41"/></g>

		
	
</svg>Sens in human erythroleukemic K562 cells. Here we have extended those studies by investigating the photopotency of <svg style="vertical-align:-3.27605pt;width:33.424999px;" id="M6" height="15.25" version="1.1" viewBox="0 0 33.424999 15.25" width="33.424999"      xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,0,0,-.017,.062,11.113)"><use xlink:href="#x55"/></g><g transform="matrix(.017,0,0,-.017,12.574,11.113)"><use xlink:href="#x56"/></g>

			<g transform="matrix(.012,0,0,-.012,24.525,15.188)"><use xlink:href="#x41"/></g>

		
	
</svg>Sens in four haematological cell lines, namely, K562, T-cell leukaemic CEM-CCRF, P-glycoprotein overexpressing R100, and transformed B-lymphoblastoid cell lines (LCL) cells. In addition, we investigated the effects of suberoylanilide hydroxamic acid in combination with <svg style="vertical-align:-3.27605pt;width:33.424999px;" id="M7" height="15.25" version="1.1" viewBox="0 0 33.424999 15.25" width="33.424999"      xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,0,0,-.017,.062,11.113)"><use xlink:href="#x55"/></g><g transform="matrix(.017,0,0,-.017,12.574,11.113)"><use xlink:href="#x56"/></g>

			<g transform="matrix(.012,0,0,-.012,24.525,15.188)"><use xlink:href="#x41"/></g>

		
	
</svg>Sens. Using <i  >&#x3b3;</i>H2AX as the endpoint, our findings indicate that <svg style="vertical-align:-3.27605pt;width:33.424999px;" id="M8" height="15.25" version="1.1" viewBox="0 0 33.424999 15.25" width="33.424999"      xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,0,0,-.017,.062,11.113)"><use xlink:href="#x55"/></g><g transform="matrix(.017,0,0,-.017,12.574,11.113)"><use xlink:href="#x56"/></g>

			<g transform="matrix(.012,0,0,-.012,24.525,15.188)"><use xlink:href="#x41"/></g>

		
	
</svg>Sens-induced phototoxicity in all four of the haematological cell lines. The addition of suberoylanilide hydroxamic acid augmented the photopotency of <svg style="vertical-align:-3.27605pt;width:33.424999px;" id="M9" height="15.25" version="1.1" viewBox="0 0 33.424999 15.25" width="33.424999"      xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.017,0,0,-.017,.062,11.113)"><use xlink:href="#x55"/></g><g transform="matrix(.017,0,0,-.017,12.574,11.113)"><use xlink:href="#x56"/></g>

			<g transform="matrix(.012,0,0,-.012,24.525,15.188)"><use xlink:href="#x41"/></g>

		
	
</svg>Sens highlighting the potential clinical applicability of combination therapies.

Annabelle L. Rodd

Katherine Ververis

Tom C. Karagiannis

Combination Phototherapy with a Histone Deacetylase Inhibitor and a Potent DNA-Binding Bibenzimidazole: Effects in Haematological Cell Lines

Cutaneous T-cell lymphoma is a term that encompasses a spectrum of non-Hodgkin&#x2019;s T-cell lymphomas with primary manifestations in the skin. It describes a heterogeneous group of neoplasms that are characterised by an accumulation of malignant T cells of the CD4 phenotype that have the propensity to home and accumulate in the skin, lymph nodes, and peripheral blood. The two most common variants of cutaneous T-cell lymphoma include mycosis fungoides and the leukemic variant, the S&#xe9;zary syndrome. While numerous treatments are available for cutaneous T-cell lymphoma and have shown to have success in those with patch and plaque lesions, for those patients with tumour stage or lymph node involvement there is a significant decline in response. The relatively new therapeutic option with the use of histone deacetylase inhibitors is being advanced in the hope of decreasing morbidity and mortality associated with the disease. Histone deacetylase inhibitors have been shown to induce changes in gene expression, affecting cell cycle regulation, differentiation, and apoptosis. The aim of this paper is to discuss CTCL in the context of advances in CTCL treatment, specifically with HDAC inhibitors.

Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors

Today AIDS-related non-Hodgkin&#x27;s lymphoma (AR-NHL) is a significant cause of morbidity and mortality in HIV-infected patients the world over, and especially in sub-Saharan Africa. While the overall incidence of AR-NHL since the emergence of combination antiretroviral therapy (cART) era has declined, the occurrence of this disease appears to have stabilized. In regions where access to cART is challenging, the impact on disease incidence is less clear. In the resource-rich environment it is clinically recognized that it is no longer appropriate to consider AR-NHL as a single disease entity and rather treatment of AIDS lymphoma needs to be tailored to lymphoma subtype. While intensive therapeutic strategies in the resource-rich world are clearly improving outcome, in AIDS epicenters of the world and especially in sub-Saharan Africa there is a paucity of data on treatment and outcomes. In fact, only one prospective study of dose-modified oral chemotherapy and limited retrospective studies with sufficient details provide a window into the natural history and clinical management of this disease. The scarcities and challenges of treatment in this setting provide a backdrop to review the current status and realities of the therapeutic approach to AR-NHL in sub-Saharan Africa. More pragmatic and risk-adapted therapeutic approaches are needed.

Peter M. Mwamba

Walter O. Mwanda

Naftali W. Busakhala

R. Matthew Strother

Patrick J. Loehrer

Scot C. Remick

AIDS-Related Non-Hodgkin&#x27;s Lymphoma in Sub-Saharan Africa: Current Status and Realities of Therapeutic Approach

About this journal

Journal profile

Meet the editorial board

Editor spotlight

Find out more

This journal's articles appear in a wide range of abstracting and indexing databases, and are covered by numerous other services that aid discovery and access. Find out more about where and how the content of this journal is available.

Lymphoma